Physician profile
Jason Smith
NPI 1578586400
$272,243.30
in general payments reported to CMS, 2019-2025
47 companies · $20K in 2025
The $20K reported for 2025 was more than what 92% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $9,792 · 2021: $18K · 2022: $45K · 2023: $56K · 2024: $51K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $81K · Consulting Fee: $32K · Food and Beverage: $11K · Travel and Lodging: $2,672 · Education: $445 · Honoraria: $30.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,217.50 |
| Consulting Fee | $31,745.00 |
| Food and Beverage | $11,303.26 |
| Travel and Lodging | $2,672.47 |
| Education | $444.85 |
| Honoraria | $30.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $57,302.55 | 2019-2025 | |
| Ucb, INC. | $33,506.40 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $31,941.89 | 2019-2025 | Olumiant, Ebglyss, Taltz |
| Abbvie INC. | $25,068.14 | 2019-2025 | Skyrizi, Rinvoq |
| Incyte Corporation | $21,040.62 | 2021-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $19,754.25 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $13,059.47 | 2019-2025 | Absorica Ld, Winlevi, Blu-U |
| Galderma Laboratories, L.P. | $10,755.67 | 2019-2025 | Nemluvio, Oracea, Twyneo |
| Leo Pharma INC. | $8,712.35 | 2019-2025 | Adbry, Anzupgo |
| Almirall LLC | $6,749.46 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $6,708.30 | 2022-2025 | Sotyktu |
| Genentech USA, INC. | $5,599.01 | 2019-2024 | Erivedge |
| Epi Health, LLC | $4,659.71 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $3,569.13 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $3,272.50 | 2019-2024 | Targretin, Siliq, Duobrii |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.